Bristol Myers Squibb reported strong fourth-quarter earnings but its outlook for 2025 failed to meet expectations.

Bristol Myers Squibb's Breyanzi showed strong efficacy in Phase 2 lymphoma trial, meeting key endpoints. FDA approvals expand ...

Citi analyst Geoff Meacham maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report) today and set a price target of $65.00. The ...

Bristol Myers Squibb said it has received positive results for its latest lymphoma treatment trials, the fifth type of cancer the drug has been shown to treat.

The company also issued a 2025 guidance that fell short of expectations, as some of the company’s older drugs face ...

In a report released today, Srikripa Devarakonda from Truist Financial reiterated a Buy rating on Bristol-Myers Squibb (BMY – Research Report).

Bristol Myers Squibb (BMY) came out with quarterly earnings of $1.67 per share, beating the Zacks Consensus Estimate of $1.46 per share. This compares to earnings of $1.70 per share a year ago.

Bristol Myers Squibb will cut $2 billion in costs by the end of 2027, a move aimed at long-term growth as the company prepares for patent expirations on key treatments, CNBC reported Feb. 6.

Bristol-Myers Squibb (BMY) shares are under pressure after the company provided soft guidance due to competition among generic drugmakers. Peloton (PTON) stock jumps after beating on earnings and ...

BRISTOL-MYERS SQUIBB ($BMY) posted quarterly earnings results on Thursday, February 6th. The company reported earnings of $1.67 per share, beating estimates of $1.47 ...